Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2007; 28(01): 20-25
DOI: 10.1055/s-0041-1733199
Original Article

Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia

L Abraham Jacob
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore-560 029, India
,
PP Bapsy
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore-560 029, India
,
K Govind Babu
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore-560 029, India
,
Lokanatha › Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2007. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bhutani M and Kochupillai V. Hematological malignancies in India, in Kumar L (editor): Progress in Hematologic Oncology. Pub. The Advanced Research Foundation New York, New York 2003,p10.
  • 2 Deninger MW, O’Brien SG, Ford JM et al: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.
  • 3 Kantarjian H, Swayers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645
  • 4 O’Dweyer ME, Mauro MJ, Blasdel C, et al: Lack of cytogenetics response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI 571). Blood 2001;98:137a (abstr 579).
  • 5 Arora B, Kumar L, Kumari M, et al: Therapy with imatinib mesylate for chronic myeloid leukemia. Ind Jn Med and Paed Oncology 2005;26:5-16.
  • 6 Desmukh C, Saikia T, Bakshi A, et al: Imatinib mesylate in chronic myeloid leukemia: A prospective, single arm, non-randomised study. JAPI 2005;53:291-295.
  • 7 Vardiman JW, Harris NL, Brunning RD. The World Health Organisation (WHO) classification of myeloid neoplasms. Blood 2002;100:2292-302.
  • 8 Druker BJ and Lee SJ. Chronic leukemias, In Devita VT, Hellman S, and Rosenberg SA (editors): Cancer, Principles and practice of Oncology. Pub. Lippincott, Philadelphia. 2005.7thedition p2124
  • 9 O’Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003;348:994-1004.
  • 10 Kantarjian HM, Cortes JE, O’Brien S, et al: Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;1,101(1):97-100.
  • 11 Velpandian T, Mathur R, Agarwal NK et al. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J. Chromatogr B Analyt Technol Biomed life sci, 2004; 804:431-4.